High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

Responses, Treatment-Related Morbidity, and Histologic Findings

Michael T. Lotze, Alfred E. Chang, Claudia A. Seipp, Colleen Simpson, John T. Vetto, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Experience with the administration of high doses of interleukin 2 (IL-2) alone is described herein. Ten patients with a variety of malignant disorders unresponsive to conventional treatments were treated with at least 30 000 U/kg of IL-2 by bolus administration three times a day. Patients were treated intravenously or intraperitoneally from four to 21 days in a single course, usually interrupted by a week of recovery. Three of six patients with melanoma experienced an objective regression (>50% decrease in volume); there was no response to treatment in patients with colorectal (0/3) or ovarian (0/1) cancer. Two patients with initial objective regressions who subsequently developed progression were re-treated and one sustained a second partial response. Responses lasted 1, 3, and 7 months without additional treatment. Responses in the three patients with melanoma were in visceral sites (lung, liver, and spleen), as well as cutaneous sites in one patient. Progressive shrinkage of tumors for three to six months after the conclusion of therapy has been noted in two patients. Marked lymphocytic infiltrate was noted in a patient with lesions accessible to repeated biopsies. This study demonstrates that the administration of IL-2 can mediate the regression of established cancer in some patients.

Original languageEnglish (US)
Pages (from-to)3117-3124
Number of pages8
JournalJournal of the American Medical Association
Volume256
Issue number22
DOIs
StatePublished - Dec 12 1986
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Interleukin-2
Morbidity
Therapeutics
Melanoma
Neoplasms
Spleen
Biopsy
Lung
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer : Responses, Treatment-Related Morbidity, and Histologic Findings. / Lotze, Michael T.; Chang, Alfred E.; Seipp, Claudia A.; Simpson, Colleen; Vetto, John T.; Rosenberg, Steven A.

In: Journal of the American Medical Association, Vol. 256, No. 22, 12.12.1986, p. 3117-3124.

Research output: Contribution to journalArticle

Lotze, Michael T. ; Chang, Alfred E. ; Seipp, Claudia A. ; Simpson, Colleen ; Vetto, John T. ; Rosenberg, Steven A. / High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer : Responses, Treatment-Related Morbidity, and Histologic Findings. In: Journal of the American Medical Association. 1986 ; Vol. 256, No. 22. pp. 3117-3124.
@article{c2333270d8414b209c65a0629f0f4fca,
title = "High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer: Responses, Treatment-Related Morbidity, and Histologic Findings",
abstract = "Experience with the administration of high doses of interleukin 2 (IL-2) alone is described herein. Ten patients with a variety of malignant disorders unresponsive to conventional treatments were treated with at least 30 000 U/kg of IL-2 by bolus administration three times a day. Patients were treated intravenously or intraperitoneally from four to 21 days in a single course, usually interrupted by a week of recovery. Three of six patients with melanoma experienced an objective regression (>50{\%} decrease in volume); there was no response to treatment in patients with colorectal (0/3) or ovarian (0/1) cancer. Two patients with initial objective regressions who subsequently developed progression were re-treated and one sustained a second partial response. Responses lasted 1, 3, and 7 months without additional treatment. Responses in the three patients with melanoma were in visceral sites (lung, liver, and spleen), as well as cutaneous sites in one patient. Progressive shrinkage of tumors for three to six months after the conclusion of therapy has been noted in two patients. Marked lymphocytic infiltrate was noted in a patient with lesions accessible to repeated biopsies. This study demonstrates that the administration of IL-2 can mediate the regression of established cancer in some patients.",
author = "Lotze, {Michael T.} and Chang, {Alfred E.} and Seipp, {Claudia A.} and Colleen Simpson and Vetto, {John T.} and Rosenberg, {Steven A.}",
year = "1986",
month = "12",
day = "12",
doi = "10.1001/jama.1986.03380220083027",
language = "English (US)",
volume = "256",
pages = "3117--3124",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "22",

}

TY - JOUR

T1 - High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

T2 - Responses, Treatment-Related Morbidity, and Histologic Findings

AU - Lotze, Michael T.

AU - Chang, Alfred E.

AU - Seipp, Claudia A.

AU - Simpson, Colleen

AU - Vetto, John T.

AU - Rosenberg, Steven A.

PY - 1986/12/12

Y1 - 1986/12/12

N2 - Experience with the administration of high doses of interleukin 2 (IL-2) alone is described herein. Ten patients with a variety of malignant disorders unresponsive to conventional treatments were treated with at least 30 000 U/kg of IL-2 by bolus administration three times a day. Patients were treated intravenously or intraperitoneally from four to 21 days in a single course, usually interrupted by a week of recovery. Three of six patients with melanoma experienced an objective regression (>50% decrease in volume); there was no response to treatment in patients with colorectal (0/3) or ovarian (0/1) cancer. Two patients with initial objective regressions who subsequently developed progression were re-treated and one sustained a second partial response. Responses lasted 1, 3, and 7 months without additional treatment. Responses in the three patients with melanoma were in visceral sites (lung, liver, and spleen), as well as cutaneous sites in one patient. Progressive shrinkage of tumors for three to six months after the conclusion of therapy has been noted in two patients. Marked lymphocytic infiltrate was noted in a patient with lesions accessible to repeated biopsies. This study demonstrates that the administration of IL-2 can mediate the regression of established cancer in some patients.

AB - Experience with the administration of high doses of interleukin 2 (IL-2) alone is described herein. Ten patients with a variety of malignant disorders unresponsive to conventional treatments were treated with at least 30 000 U/kg of IL-2 by bolus administration three times a day. Patients were treated intravenously or intraperitoneally from four to 21 days in a single course, usually interrupted by a week of recovery. Three of six patients with melanoma experienced an objective regression (>50% decrease in volume); there was no response to treatment in patients with colorectal (0/3) or ovarian (0/1) cancer. Two patients with initial objective regressions who subsequently developed progression were re-treated and one sustained a second partial response. Responses lasted 1, 3, and 7 months without additional treatment. Responses in the three patients with melanoma were in visceral sites (lung, liver, and spleen), as well as cutaneous sites in one patient. Progressive shrinkage of tumors for three to six months after the conclusion of therapy has been noted in two patients. Marked lymphocytic infiltrate was noted in a patient with lesions accessible to repeated biopsies. This study demonstrates that the administration of IL-2 can mediate the regression of established cancer in some patients.

UR - http://www.scopus.com/inward/record.url?scp=84944285022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944285022&partnerID=8YFLogxK

U2 - 10.1001/jama.1986.03380220083027

DO - 10.1001/jama.1986.03380220083027

M3 - Article

VL - 256

SP - 3117

EP - 3124

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 22

ER -